Hematopoietic lineage cells

Hematopoietic lineage cells represent the diverse population of blood cells and their precursors derived from multipotent hematopoietic stem cells in the bone marrow (Jagannathan-Bogdan & Zon, 2013). This broad category includes the myeloid lineage, which produces erythrocytes, megakaryocytes, and granulocytes, and the lymphoid lineage, which produces T cells, B cells, and natural killer cells (NIH, 2023). These cells are essential for physiological processes such as oxygen transport, immune defense, and hemostasis. While these cells are the site of origin for numerous pathologies, including leukemias, lymphomas, and various anemias, the term Hematopoietic lineage cells refers to a cellular population rather than a discrete molecular target like a receptor or enzyme (StatPearls, 2023). In drug development, therapeutic agents are designed to interact with specific proteins expressed by these cells, such as CD20 on B cells or BCR-ABL in chronic myeloid leukemia, rather than the lineage as a whole (PubMed, 2022). Consequently, this entry is classified as incorrect for a molecular target database because it lacks the specificity required to define a single therapeutic mechanism of action.

Other names

Hematopoietic cellsBlood cellsHematopoietic systemMyeloid and lymphoid lineagesHLCs

Not applicable as this refers to a broad cell population rather than a specific molecular target.